These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32705581)

  • 1. Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
    Pikatan NW; Liu YL; Bamodu OA; Hsiao M; Hsu WM; Haryana SM; Sutaryo ; Chao TY; Yeh CT
    Cell Oncol (Dordr); 2020 Dec; 43(6):1067-1084. PubMed ID: 32705581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
    O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
    Front Immunol; 2019; 10():2129. PubMed ID: 31552054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase (BTK) inhibitors alter blood glucose and insulin in obese mice but reduce inflammation independent of BTK.
    Chan DY; Barra NG; Fang H; Rodrigues E-Lacerda R; Schertzer JD
    Am J Physiol Endocrinol Metab; 2024 Sep; 327(3):E271-E278. PubMed ID: 39017678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
    Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
    Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting Bruton's Tyrosine Kinase to Counteract Chemoresistance and Stem Cell-Like Properties in Osteosarcoma.
    Tsai HC; Lien MY; Wang SW; Fong YC; Tang CH
    Environ Toxicol; 2024 Nov; 39(11):4936-4945. PubMed ID: 38924303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
    Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
    Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.
    Zucha MA; Wu AT; Lee WH; Wang LS; Lin WW; Yuan CC; Yeh CT
    Oncotarget; 2015 May; 6(15):13255-68. PubMed ID: 26036311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
    Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
    Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
    Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
    J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.
    Li T; Deng Y; Shi Y; Tian R; Chen Y; Zou L; Kazi JU; Rönnstrand L; Feng B; Chan SO; Chan WY; Sun J; Zhao H
    Oncogene; 2018 Nov; 37(47):6180-6194. PubMed ID: 30013190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
    Roman-Garcia S; Merino-Cortes SV; Gardeta SR; de Bruijn MJW; Hendriks RW; Carrasco YR
    Front Immunol; 2018; 9():2027. PubMed ID: 30237801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
    O'Riordan CE; Purvis GSD; Collotta D; Krieg N; Wissuwa B; Sheikh MH; Ferreira Alves G; Mohammad S; Callender LA; Coldewey SM; Collino M; Greaves DR; Thiemermann C
    Front Immunol; 2020; 11():581758. PubMed ID: 33162995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation.
    Kim JM; Park J; Noh EM; Song HK; Kang SY; Jung SH; Kim JS; Park BH; Lee YR; Youn HJ
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
    Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
    Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
    Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
    PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.